BioSpecifics Technologies Corp. to Present at the 16th Annual Needham Healthcare Conference

LYNBROOK, N.Y., March 29, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum (CCH) marketed as XIAFLEX^® in the U.S. and Xiapex^® in Europe, today announced that management will present a corporate overview at the upcoming 16^th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 8:00 a.m. ET in New York, NY.

A live webcast of the presentation can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com or at http://wsw.com/webcast/needham80/bstc.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Europe and Australia. Endo is partnered with Sobi, Actelion and Asahi Kasei for Dupuytren's contracture and Peyronie's disease outside the U.S. The XIAFLEX research and development pipeline includes several additional promising indications. BioSpecifics is managing the development of XIAFLEX for uterine fibroids and plans to initiate clinical development in the first quarter of 2017. For more information, please visit www.biospecifics.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-the-16th-annual-needham-healthcare-conference-300431186.html

SOURCE BioSpecifics Technologies Corp.